JC05 Rec' CT/PTO 24 AUG 2005

Patent Docket P1995R1

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Fong et al.

Serial No.: 10/533,416 ~

Filed: April 28, 2005

For: COMPOSITION AND METHODS FOR

THE TREATMENT OF NATURAL KILLER

**CELL RELATED DISEASES** 

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Confirmation No: Not Yet Assigned

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 22,2005

Bailey Lee

### **INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

#### [x] 37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

### [] 37 CFR §1.97(c)

 by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of Serial No.: 10/533416 Filing Date: April 28, 2005

Page 2

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

## [] 37 CFR §1.97(d)

 after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filling of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filling of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (\*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR § 1.98(a)(2)(ii)]. See Final Rule 1287 OG (October 12, 2004). Other documents cited with an asterisk have not been supplied because they were previously cited by or submitted to the Office in prior application Serial No. FIELD(Parent SN), filed FIELD(Parent Date) and benefit from the prior application is claimed in this application under 35 U.S.C § 120. However, copies of any cited

Serial No.: 10/533416 Filing Date: April 28, 2005

Page 3

document will be provided in its entirety at the request of the Office.

A concise explanation of relevance of the items listed on PTO-1449 is:

[X] not given

Date: August 62, 2005

- [] given for each listed item
- [] given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC

David A. Carpenter

Reg. No45,945

Telephone No. (650) 225-43733

Chast	1	-1	1
Sheet	1	OI.	1

FORM PTO-1449		U.S. Dept. of Commerce	Atty Docket No.			Serial No. 10/533416		
Patent and Trademark Office			Applicant					
LIST	OF DIS	SCLOSURES CITED B	Y APPLICANT		Fong Sher	rman et a	1.	
0.1	ca cav	oral choots if noncessan	v)	·	Filing Date		Group	)
(Use several sheets if necessary)				28 Apr		<u>'</u>		
		,		FOREIGN PATENT DOCUMENTS	S			
Examiner nitials		Document Number	Date	Country	Cla	ss S	ubclass	Translation Yes No
	1	WO 01/75166 A2	11.10.01	PCT				
				OSURES (Including Author, Title, Date,				
	2	Dalbeth et al., " Rheum. 46(7):1763		ural killer cells is greatly ex 2)	panded with	nin infla	med joir	ts" <u>Arthriti</u>
	3	Kohler and Milste Nature 256:495-49		us Cultures of Fused Cells Secre	ting Antibo	ody of Pr	edefined	Specificity
	4	Wenzel et al., "N thyroiditis" Thyr		cell activity in patients with G -1022 (Nov 1998)	raves' dise	ease and	Hashimot	o's
								·
	• •			, <u> </u>				
							<del></del>	
			•	*	<del></del>			<u> </u>
			·········					
						5		<del>-</del>
	2 1							· , —
				-				
						-		
Examine	r			D	ate Considere	d		
*Examin	er: Ini	tial if reference consid-	lered, whether or no	ot citation is in conformance with MPEP by of this form with next communication	609; draw lin	e through o	citation	